Frazier Life Sciences Acquisition Corp. II (FLSC) Prices $75M IPO

Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “FLSC” on Wednesday, October 14, 2026.

The new SPAC aims to combine with a biotech company developing new therapies for patients.

Frazier Life Sciences Acquisition Corp. II is to be led by Chief Executive Officer Albert Cha, MD, PhD, Chief Financial Officer Fran Adams, Chief Business Officer Kevin Li, MD, Ali Jackson, JD, and Chairman Benjamin L. Palleiko. William C. Fairley Jr. and R. Scott Struthers, PhD, will serve on its Board of Directors.

Total SPAC deal count for 2026 year-to-date is now 155. This offering is expected to close on Thursday, October 15, 2026.

Jefferies is acting as the sole book-running manager for the offering. Goodwin Procter LLP is serving as Issuer’s Counsel with White & Case LLP is serving as Underwriter’s Counsel. CBIZ CPAs serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.